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This study was originally designed as a phase I/II study, with a dose escalation of docetaxel in combination with epirubicin 50mgm
2
and 5-fluorouracil (5-FU) 200mgm
2day
1. However, as dose escalation was not possible, the study is reported as a phase II study
of the combination to assess response and toxicity. A total of 51 patients with locally advanced or metastatic breast cancer were
treated on this phase II study, with doses of docetaxel 50mgm
2, epirubicin 50mgm
2 and infusional 5-FU 200mgm
2day
1 for 21
days. The main toxicity of this combination was neutropenia with 89% of patients having grade 3 and 4 neutropenia, and 39% of
patients experiencing febrile neutropenia. Nonhaematological toxicity was mild. The overall response rate in the assessable patients
was 64%, with median progression-free survival of 38 weeks, and median survival of 70 weeks. The ETF regimen was found to be
toxic, and it was not possible to escalate the dose of docetaxel above the first dose level. This regimen has therefore not been taken
any further, but as a development of this a new study is ongoing, combining 3-weekly epirubicin, weekly docetaxel and capecitabine,
days 1–14.
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The treatment of metastatic or advanced breast cancer has evolved
over the last few years, and in the 1990s this was largely due to the
introduction of the taxane family of drugs. Docetaxel (taxotere) is
a semisynthetic taxane derived from 10-deacetyl baccatin III, a
precursor isolated from the needles of Taxus baccata. As with the
other taxane compounds, it acts by promoting microtubule
assembly and inhibiting microtubule depolymerisation. This
blocks cells in M phase and so prevents cell division.
Docetaxel has well-documented activity in advanced breast
cancer with a single agent dose of 100mgm
2. The dose-limiting
toxicity of docetaxel is grade 3 and 4 neutropenia. The response
rate ranges from 19–57% in pretreated patients and 54–67% in
those with minimal pretreatment (Clemons et al, 1997).
Following the single-agent studies, docetaxel was combined with
other active agents. The most attractive combination, initially, was
with anthracyclines, as docetaxel is known to have activity in
anthracycline-resistant disease (Miller et al, 2001). Studies were
carried out using epirubicin and docetaxel. For example, docetaxel
was escalated with a fixed dose of epirubicin (Venturini et al,
2001). It was found that the dose-limiting toxicity was neutropenia,
which was ameliorated to some extent by G-CSF. Other side effects
were mild. There were however two toxic deaths. The recom-
mended doses for further investigation were epirubicin 75mgm
2
and docetaxel 80mgm
2. In a further study (Viens et al, 2001),
escalating doses of epirubicin were given with a fixed dose of
docetaxel 75mgm
2. Dose-limiting toxicities were grade 3 and 4
asthenia, febrile neutropenia and stomatitis and diarrhoea. There
was an overall response rate of 69.4%, and a median duration of
response of 7.8 months. The recommended dose was epirubicin
100mgm
2 with docetaxel 75mgm
2. An overview of these
studies in 2001 (Trudeau and Pagani, 2001) concluded that
epirubicin and docetaxel was effective, with high response rates,
and no significant cardiotoxicity.
Docetaxel has also been combined with 5-fluorouracil (5-FU). A
phase I study (Lortholary et al, 2000) escalated doses of docetaxel,
given on day 1, along with escalating doses of 5-FU given as a 5-
day intravenous infusion, every 3 weeks. The most common
toxicity was grade 4 neutropenia, which occurred in 91% of
patients. The recommended dose for phase II studies was
85mgm
2 docetaxel with 750mgm
2day
1 5-FU for 5 days.
At the time this study was initiated, a very active regimen that
was used was the ECF regimen of epirubicin, 50mgm
2, cisplatin,
60mgm
2 and infusional 5-FU, 200mgm
2day
1. A phase II
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lstudy of eight courses of ECF in 43 patients with metastatic and
locally advanced breast cancer (Jones et al, 1994) gave an overall
response rate of 84%. This regimen has also been used in a phase II
study in patients with large but operable breast cancer in the
neoadjuvant setting (Smith et al, 1995). A total of 50 patients were
treated with an overall response rate of 98% and 66% complete
response rate. Grade 3 and 4 toxicities were rare. The ECF regimen
was of sufficient interest to investigate it further in phase III
studies in both the neoadjuvant (TOPIC Trial) and high-risk
adjuvant (TRAFIC) settings.
The ECF regimen, in general, is well tolerated. However, the
inclusion of cisplatin in the regimen usually necessitates an
overnight stay for each course of treatment. We therefore looked at
the possibility of using epirubicin and 5-FU in the doses used in
the ECF regimen, but combining them with docetaxel, a very active
agent in metastatic breast cancer, which can be given as an
outpatient.
STUDY OBJECTIVES
The original intention of this study was to perform a dose escalation
study of docetaxel in combination with epirubicin (50mgm
2) and
continuous infusional 5-fluorouracil (200mgm
2day
1), and then
to carry out a phase II study at the defined doses in patients with
metastatic or advanced primary breast cancer. However, dose
escalation of docetaxel was not possible, due to toxicity, and it is
therefore reported as a phase II study.
PATIENTS AND METHODS
Study design
This phase II study of the ETF combination was carried out at the
initial dose of docetaxel in the phase I design, 50mgm
2,i n
patients with metastatic or advanced primary breast cancer, to
assess response rate and toxicity.
The study was approved by the local ethics committee of each
hospital carrying out the study.
Data collection and statistical analysis
The study was carried out in five different cancer units within
Yorkshire. The data was collected and analysed at the cancer
centre. Survival and progression-free survival were analysed by the
Kaplan–Meier method.
Patient selection
Eligible patients were 70 years or less with histologically
confirmed advanced or metastatic breast cancer. Previous
adjuvant or neoadjuvant chemotherapy was permitted, which
could be anthracycline based, if completed at least 18 months
prior to study entry. Previous endocrine and radiotherapy were
permitted.
Patients were to be of Eastern Cooperative Oncology Group
(ECOG) performance status 0, 1 or 2 and have a life expectancy of
at least 3 months. They must not have uncontrolled brain
metastases, have no other serious medical conditions, no history
of significant cardiac disease, adequate baseline bone marrow
(neutrophils X1.510
9l
1 and platelets X10010
9l
1) and
hepatic (normal bilirubin, transaminase p3 times upper limit of
normal) function, no previous exposure to taxanes and fully
recovered from previous therapies. Patients were not pregnant or
lactating.
Most patients had either measurable or evaluable disease.
However, those who were entered as part of the phase I study
did not necessarily have either measurable or evaluable disease.
All patients were required to give written informed consent
prior to entry into the study.
Treatment plan
All patients required a central line to be inserted prior to
chemotherapy to deliver the continuous infusional 5-FU. To
reduce the risk of thrombosis, all patients were started on a
minimum of warfarin 1mgday
1, but exact warfarin regimens
were left to individual units practice.
Docetaxel was given as a 1h infusion with standard steroid
prophylaxis, followed by epirubicin as an intravenous bolus, on
day 1. 5-Fluorouracil was given by continuous intravenous
infusion via a central line and a portable pump.
In order to proceed to the next cycle of chemotherapy, the
required neutrophil count was X1.510
9l
1. No G-CSF was used
in this study.
Patient evaluation
Prior to beginning the treatment, all patients underwent a
physical examination, including height and weight, a full blood
count (FBC), urea and electrolytes (U&E), liver function tests
and bone biochemistry. While on study, all patients had
weekly FBC. Urea and electrolytes, liver function tests and
bone biochemistry were carried out prior to each course of
chemotherapy.
Patients underwent a baseline chest X-ray, a bone scan for
known or suspected metastases and a CT or ultrasound of the liver.
Patients had documentation of other disease sites, either clinically,
photographed, or by means of suitable imaging.
Disease response was documented after three and six cycles of
chemotherapy.
Response criteria and end points
The end points for the study were toxicity, response and response
duration, where patients had clinically evaluable disease and
survival.
Response was assessed after three and six courses of
chemotherapy, either clinically or by radiological means. Res-
ponse was graded by WHO criteria, as complete response
(CR), partial response (PR), stable disease (SD) or progressive
disease (PD).
Dose modifications
Toxicity was graded according to the Common Toxicity Criteria.
Haematological toxicity was recorded weekly. Dose-limiting
toxicity was defined as grade 4 neutropenia or thrombocytopenia,
lasting for 1 week or longer, or with fever (single oral temperature
438.51C or three temperatures of 4381C within 24h) lasting more
than 2 days. This resulted in a reduction of all drugs by 25% in the
next and subsequent cycles. If there was further symptomatic
grade 4 haematological toxicity there was a further dose reduction,
to 50% of starting dose.
For all grade 3 nonhaematological toxicities, the dose of
specific drugs was reduced by 25%. For example, for mucositis,
palmar-plantar syndrome or diarrhoea, 5-Fluorouracil dose was
reduced by 25%. If grade 3 mucositis occurred despite this dose
reduction, then both taxotere and epirubicin were reduced,
also by 25%, on the next course of treatment. However, for
grade 2 neuropathy, a 25% dose reduction of taxotere was made,
and for grade 3 or 4 neuropathy the patient was withdrawn from
the study.
Hypersensitivity reactions were treated according to local policy.
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lRESULTS
Patient characteristics
In total, 51 patients were entered onto the study and treated
between January 1997 and June 1999.
The median age of the patients was 47 years (range, 33–67). A
total of 44 patients (86%) were treated for metastatic disease and
seven (14%) had locally advanced breast cancer. As the study was
originally set up as a phase I leading to a phase II study, six
patients received ETF with nonassessable disease, for example,
bone metastases alone, or resected lymph nodes. Eighteen patients
(35%) had had no previous treatment for breast cancer in either
the adjuvant or metastatic setting; 23 (45%) had received adjuvant
chemotherapy (12 anthracycline based and 11 CMF); 25 (49%)
adjuvant radiotherapy and 27 (53%) adjuvant endocrine therapy.
Of the 51 patients treated, 21 (41%) had liver metastases, 11 (22%)
had bone metastases, nine (18%) had locally advanced breast
primary, nine (18%) had metastatic lymph nodes and six (12%)
had lung metastases.
Toxicity
In total, 261 courses of ETF chemotherapy were given. The number
of patients who received six full courses of chemotherapy, as
planned, with no delays was 13 (25%). All other patients required
dose reductions, dose delays or the chemotherapy was stopped
early because of neutropenic sepsis (11 patients), mucositis (eight),
line problems (six), personal reasons (three), progressive disease
(two) and others (six), including Herpes zoster infection and a
chest infection.
In all, 15% of planned doses were not given, due to toxicity or
PD.
Haematological toxicity
In a small number of cases (18 courses), a weekly full blood count
was not carried out.
This chemotherapy regimen was found to cause significant
haematological toxicity as 89% patients had grade 3 or 4
neutropenia, with 39% patients experiencing episodes of neutro-
penic sepsis, Table 1. In total, 24 of 261 courses of chemotherapy
given (9%) were complicated by febrile neutropenia. One patient
had grade 4 neutropenia following her first course of ETF, with a
white cell count of 0.3 and a neutrophil count of 0.03. She was
admitted to hospital and treated with intravenous antibiotics, but
was found to have typhilitis, neutropenic enterocolitis, and
ultimately died from this. This is an uncommon but recognised
complication of patients receiving aggressive chemotherapy, and
has been described in patients who have had docetaxel (Cardenal
et al, 1996). A further patient was admitted to another hospital
following her third course of ETF chemotherapy. She was
neutropenic and was septic. Despite intravenous antibiotics she
became more unwell and subsequently died from the infection.
Only one patient had grade 3 anaemia, and no patient had
significant thrombocytopenia.
Nonhaematological toxicity
The nonhaematological toxicity was, in general, mild, compared to
the haematological toxicity and was mostly grade 1 and 2. The
most prevalent problems were grades 1 and 2 mucositis (41%),
grades 1 and 2 lethargy (29%) and grades 1 and 2 diarrhoea (25%).
However, central lines were a problem, being the source of toxicity
in 24 (46%) patients in total. The most prevalent problem was line
infections, which occurred in 12 patients, and seven lines were
removed because of infection. Four patients experienced throm-
bosis associated with their lines and a further four experienced
pain. Two patients had episodes of mediastinitis, which required
removal of the line, and one of these received bolus 5-FU for the
remainder of the courses.
In relation to the use of docetaxel, two patients developed a
photosensitive skin rash, both grade 2, and in one patient the
chemotherapy was stopped. One patient developed grade 1
neurotoxicity.
Response
The median follow-up of all patients from study entry to the date
last seen or the date of death was 70 weeks (range 1–242).
Of the 51 patients, nine did not have assessable disease: four
patients had bone metastases only, two patients had metastatic
disease in lymph nodes that were removed prior to chemotherapy,
one patient had one course of ETF and was then changed to FEC
because of a central line infection, and two patients died of
neutropenic sepsis. There were therefore 42 assessable patients, of
whom 27 had a response. Of these, six had a CR and 21 had a PR.
This gave an overall response rate of 64% (95% confidence
interval, 47–77%). A further nine patients had stable disease and
seven (14%) had PD.
The median progression-free survival was 38 weeks, and the
median survival was 70 weeks. Of the 51 patients treated, seven
have not yet relapsed, six have relapsed but have not died and two
patients died of chemotherapy toxicity.
DISCUSSION
There have now been several studies of epirubicin and docetaxel
carried out, but this is the first that we are aware of that combines
epirubicin, docetaxel and continuous infusional 5-FU. The
intention was to develop a regimen that could be given and
managed as an outpatient, but maintained or improved the high
response rate seen in the ECF regimen, by using docetaxel instead
of cisplatin.
In the dose escalation part of the study, the doses chosen for the
first dose level were docetaxel 50mgm
2 combined with
epirubicin 50mgm
2 and infusional 5-FU 200mgm
2day
1.I n
previous studies of epirubicin and docetaxel alone, doses of
epirubicin between 60 and 100mgm
2 were successfully combined
with docetaxel 75–80mgm
2. In this study, the dose of epirubicin
that was chosen was the same as in the ECF regimen and we
therefore expected to be able to escalate the dose of docetaxel
beyond the first dose level. However, the addition of continuous
infusional 5-FU to epirubicin and docetaxel made a significant
difference to the dose of docetaxel that was tolerable and dose
escalation was not achieved.
This study was therefore a phase II study of the ETF regimen. It
was found to be active with 64% of patients having a CR or PR.
This is a lower response rate than that found with ECF (Jones et al,
1994). However, the confidence intervals for the ETF study were
wide (47–77%), and therefore it cannot be directly compared to
the ECF data, and the number of patients in both studies was small.
The progression-free and overall survival, however, in our study
do compare favourably with the ECF study, suggesting that the
response and efficacy to ETF is similar to ECF.
Table 1 Haematological toxicity by patient and by course
Number of patients (%), grade 3 neutropenia 12 (24%)
Number of patients (%), grade 4 neutropenia 33 (65%)
Number of courses (%), grade 3 neutropenia 73 (28%)
Number of courses (%), grade 4 neutropenia 61 (23%)
Number of patients (%), febrile neutropenia 20 (39%)
Number of courses (%), febrile neutropenia 24 (9%)
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Firstly, the ratio of metastatic to locally advanced disease in the
ECF study was 2:1, whereas in the ETF study it was 6:1, although
none of these patients had received prior chemotherapy for
metastatic disease, and only 45% had received chemotherapy in
the adjuvant setting. In the ECF study, only 20% of patients had
received previous chemotherapy, but the authors did admit that
their group was highly selected, being relatively young and of good
performance status.
Secondly, more patients in the ETF study, 41%, had liver
metastases, conferring a worse prognosis, than in the ECF study
(21% of all patients treated).
Thirdly, the difference in response rate may also reflect the fact
that the dose of docetaxel was unable to be escalated beyond the
first dose level, due to the toxicity of the combination. In total, 89%
of patients had grade 3/4 neutropenia, 65% grade 4, with 39%
patients experiencing at least one episode of febrile neutropenia.
Overall, 9% of courses were complicated by febrile neutropenia,
and two patients died from toxicity of the chemotherapy.
Central lines were a major source of toxicity in this study, with
nearly half of the patients having problems with their lines,
probably due to the depth of neutropenia experienced by these
patients. The most common problem was infection, but four
patients had thrombosis of the lines, despite prophylactic warfarin,
and six patients had physical symptoms attributable to the lines.
Given the toxicity that was experienced with both the central
lines and with severe neutropenia with ETF, it was felt that this
regimen was too toxic to take into the adjuvant setting. A further
study in the advanced setting was therefore proposed, and is
currently recruiting patients. This involves the use of weekly
docetaxel, which is found to have a more favourable toxicity
profile in terms of haematological toxicity, 3-weekly epirubicin
and oral capecitabine, an oral fluoropyrimidine that is absorbed by
the intestinal mucosa and converted to 5-FU in the tissues.
A recent study of 3-weekly docetaxel7capecitabine in 511
patients with metastatic or locally advanced breast cancer showed
a significantly improved survival for the combination of drugs. We
are now testing whether the addition of epirubicin to docetaxel and
capecitabine is feasible, and if so whether it can improve the
response rates and survival of patients with metastatic breast
cancer.
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